Clinical Trials for Lapatinib

1 Open Trial

Trial TypeProtocol No. &
Open Date
Summary
TherapeuticVICCBRE1220
10/22/2012
A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib, Trastuzumab, with or without Endocrine Therapy for 12 weeks vs. 24 weeks in patients with HER2 Overexpressing Breast Cancer

Back to Find By Drug

You do not have JavaScript enabled. This site works better with JavaScript turned on.